On this blog, we have discussed all sorts of so-called alternative medicine (SCAM) but only rarely we scrutinize any of the many gadets and devices that are being promoted under the SCAM umbrella.

Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Oppenheimer analyst Michael Wiederhorn is updating its Amedisys (AMED) model following the Q4 earnings release. Amedisys is currently in the ...

Mutual of America Capital Management LLC decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED – Free Report) by ...

Amedisys has a twelve month low of $82.15 and a twelve month high of $98.95. Get Amedisys alerts: Amedisys (NASDAQ:AMED – Get Free Report) last announced its quarterly earnings results on ...

Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.

(2) Adjusted EBITDA is defined as net (loss) income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain ...

BATON ROUGE, La. (AP) — BATON ROUGE, La. (AP) — Amedisys Inc. (AMED) on Wednesday reported a fourth-quarter loss of $20.4 million, after reporting a profit in the same period a year earlier.

In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the fourth quarter and year end results.

Amedisys (AMED) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago. These figures ...